Cargando…

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina

Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Urueña, Analía, Micone, Paula, Magneres, María Cecilia, McGovern, Ian, Mould-Quevedo, Joaquin, Sarmento, Túlio Tadeu Rocha, Giglio, Norberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612026/
https://www.ncbi.nlm.nih.gov/pubmed/36298493
http://dx.doi.org/10.3390/vaccines10101627
_version_ 1784819674920255488
author Urueña, Analía
Micone, Paula
Magneres, María Cecilia
McGovern, Ian
Mould-Quevedo, Joaquin
Sarmento, Túlio Tadeu Rocha
Giglio, Norberto
author_facet Urueña, Analía
Micone, Paula
Magneres, María Cecilia
McGovern, Ian
Mould-Quevedo, Joaquin
Sarmento, Túlio Tadeu Rocha
Giglio, Norberto
author_sort Urueña, Analía
collection PubMed
description Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the payer and societal perspectives. Methods: A static decision tree model compared the costs and health benefits of vaccination with QIVc vs. QIVe using a one-year time horizon. The relative vaccine effectiveness of QIVc vs. QIVe was assumed to be 8.1% for children and 11.4% for adults. An alternative high egg-adaptation scenario was also assessed. Model inputs were sourced from Argentina or the international literature. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared to QIVe, QIVc would prevent 17,857 general practitioner visits, 2418 complications, 816 hospitalizations, and 12 deaths per year. From the payers’ perspective, the incremental cost-effectiveness ratio per quality-adjusted life years gained was USD12,214 in the base case and USD2311 in the high egg-adaptation scenario. QIVc was cost-saving from the societal perspective in both scenarios. Conclusions: QIVc in Argentina would be cost-effective relative to QIVe. The potential health benefits and savings would be even higher in high egg-adaptation seasons.
format Online
Article
Text
id pubmed-9612026
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96120262022-10-28 Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina Urueña, Analía Micone, Paula Magneres, María Cecilia McGovern, Ian Mould-Quevedo, Joaquin Sarmento, Túlio Tadeu Rocha Giglio, Norberto Vaccines (Basel) Article Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the payer and societal perspectives. Methods: A static decision tree model compared the costs and health benefits of vaccination with QIVc vs. QIVe using a one-year time horizon. The relative vaccine effectiveness of QIVc vs. QIVe was assumed to be 8.1% for children and 11.4% for adults. An alternative high egg-adaptation scenario was also assessed. Model inputs were sourced from Argentina or the international literature. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared to QIVe, QIVc would prevent 17,857 general practitioner visits, 2418 complications, 816 hospitalizations, and 12 deaths per year. From the payers’ perspective, the incremental cost-effectiveness ratio per quality-adjusted life years gained was USD12,214 in the base case and USD2311 in the high egg-adaptation scenario. QIVc was cost-saving from the societal perspective in both scenarios. Conclusions: QIVc in Argentina would be cost-effective relative to QIVe. The potential health benefits and savings would be even higher in high egg-adaptation seasons. MDPI 2022-09-28 /pmc/articles/PMC9612026/ /pubmed/36298493 http://dx.doi.org/10.3390/vaccines10101627 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Urueña, Analía
Micone, Paula
Magneres, María Cecilia
McGovern, Ian
Mould-Quevedo, Joaquin
Sarmento, Túlio Tadeu Rocha
Giglio, Norberto
Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
title Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
title_full Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
title_fullStr Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
title_full_unstemmed Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
title_short Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
title_sort cost-effectiveness analysis of cell versus egg-based seasonal influenza vaccination in children and adults in argentina
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612026/
https://www.ncbi.nlm.nih.gov/pubmed/36298493
http://dx.doi.org/10.3390/vaccines10101627
work_keys_str_mv AT uruenaanalia costeffectivenessanalysisofcellversuseggbasedseasonalinfluenzavaccinationinchildrenandadultsinargentina
AT miconepaula costeffectivenessanalysisofcellversuseggbasedseasonalinfluenzavaccinationinchildrenandadultsinargentina
AT magneresmariacecilia costeffectivenessanalysisofcellversuseggbasedseasonalinfluenzavaccinationinchildrenandadultsinargentina
AT mcgovernian costeffectivenessanalysisofcellversuseggbasedseasonalinfluenzavaccinationinchildrenandadultsinargentina
AT mouldquevedojoaquin costeffectivenessanalysisofcellversuseggbasedseasonalinfluenzavaccinationinchildrenandadultsinargentina
AT sarmentotuliotadeurocha costeffectivenessanalysisofcellversuseggbasedseasonalinfluenzavaccinationinchildrenandadultsinargentina
AT giglionorberto costeffectivenessanalysisofcellversuseggbasedseasonalinfluenzavaccinationinchildrenandadultsinargentina